# Biogen

Type: Company (BIIB)

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/biogen
Canonical HTML page: https://getlegalbrief.com/entity/biogen

## Timeline

- **2026-07-28**: High Court grants permission for judicial review — Judge Cian Ferriter allows Emily Felix's challenge against the HSE and Minister for Health to proceed, citing arguable grounds regarding the delay.
- **2025-12**: NCPE pharmacoeconomic evaluation completed — The National Centre for Pharmacoeconomics delivers its assessment of Skyclarys' cost-effectiveness to the HSE.
- **2024-08**: HSE reimbursement application filed — Biogen submits a formal pricing and reimbursement application to the HSE to add Skyclarys to the public drug list.
- **2024-02**: European market authorisation — The European Commission grants centralised marketing authorisation for Biogen's Skyclarys (omaveloxolone) for patients over 16.
- **2010**: Diagnosis with Friedreich's ataxia — Emily Felix, then 12 years old, is diagnosed with the rare, progressive neuromuscular disease.

## Recent coverage (1 stories)

### Patient Sues HSE After 23-Month Delay on Drug Available in 12 EU States
2026-08-03 15:05:07 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Emily Felix, 28, launches judicial review against the HSE for failing to decide on funding for Biogen's Friedreich's ataxia drug for nearly two years, despite EMA approval and availability across a dozen EU nations.
Full story: https://getlegalbrief.com/story/patient-sues-hse-23-month-delay-drug-12-eu

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.